Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

Market Cap

29.37 Billion CNY

Sector

Healthcare

Website

https://www.wolwobiotech.com

Description

Zhejiang Wolwo Bio-Pharmaceutical Co.

Read More

Overview

Value

4

Growth

67

Health

73

Management

73

Analyst Opinion

80

Total

59

All Scores Out Of 100

Best Features

  • Very strong cashflow and earnings growth
  • Earnings growth has improved recently
  • Has a low level of debt
  • Low risk of bankruptcy
  • Has strong financial health
  • Liked by analysts
  • Has strong dividend growth
  • Low preportion of income is paid as dividend

Risk Factors

  • Overvalued on cashflow basis
  • No margin of safety at their current market price
  • Price-to-earnings ratio of 64.9 is higher than the market average (19.6x)

Market Peers

300357.SZ

Key Figures

PE Ratio (TTM)

64.86

Margin Of Safety (DCF)

-80.14%

Revenue Growth (5 Year Average)

17.46%

Ratings Consensus

Buy

Share Buybacks

N/A

Dividend Yeild (TTM)

N/A

Valuation

Value Score

4

  • Estimated intrinsic-value of 11.18 CNY is lower than current price ( 56.10 CNY)
  • Price-to-earnings ratio of 64.9 is higher than the market average (19.6x)
  • Free-cashflow-yeild of 0.60% is worse than the market average (4.7%)
  • Margin-of-safety of -80.14% is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: < 7.2 CNY

Current Price: 56.3 CNY

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

64.86x

Free Cashflow Yeild

0.60%

PE/Earnings Growth

3.03

Price/Book

14.66x

Growth

Growth Score

67

  • 5 Year Average Revenue growth of 17.46% is higher than the market average (10.97%)
  • Revenue growth has improved this yeara
  • 5 Year Average Earnings growth of 16.95% is higher than the market average (14.48%)
  • Earnings growth has improved this year
  • 5 Year Average Cashflow growth of 18.79% is higher than the market average (12.35%)
  • Free Cashflow growth has slowed this year

Revenue Growth

17.46%

Earnings Growth

16.95%

Cashflow Growth

18.79%

Health

Health Score

73

  • Low risk of bankruptcy
  • Has a low level of debt
  • Assets cover liabilities
  • Low financial Leverage
  • Normal operation does not require debt to be sustainable
  • Debt repayments do not significantly impact cashflow

Altman Z Score

20.00

Piostroski Score

3.00

Debt/Equity

0.00x

Current Assets/Liabilities

12.42x

Free Cashflow/Total Debt

30.54x

Debt/Capital

0.01x

Dividend

Secure Dividend Score

55

  • Dividend is likely safe
  • Long term dividend payout ratio of 27.69% is considered good
  • Payout ratio (TTM) of N/A is lower than the average (40%)
  • Dividends have shown growth over the last 5 years
  • Spending a lower percentage of their income on dividends than last 5 years
  • Dividend yeild of N/A is less than the market average (1.85%)
  • Dividend growth has been slowing recently

Dividend Yeild

N/A

Dividend Growth

-11.11%

Payout Ratio (Earnings)

N/A

Payout Ratio (Cashflow)

N/A

Management

Management Score

73

  • Has not bought shares or issued new shares in the last 5 years
  • Has returned higher dividends when earnings have risen
  • Return-on-equity of 19.47% is higher than the market average (15%)
  • Return-on-capital-employed of 22.31% is higher than the market average (10%)

Average Buybacks/Dilution

N/A

Recent Buybacks/Dilution

-0.01%

5 Year Price Volitility

44.21%

Return On Assets

17.49%

Return On Capital Employed

22.31%

Return On Equity

19.47%

Return On Free Cashflow

181.64%

Return On Investments

405.49%

Analysts

Analyst Opinion

80

  • Ratings consensus is Buy

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

Currency

CNY

Beta

0.413987

Vol Avg

2383114

Ceo

Cik

Cusip

Exchange

Shenzhen

Full Time Employees

1488

Industry

Drug Manufacturers—General

Sector

Healthcare

Ipo Date

2014-01-21

Address

No. 636, Zhiyuan North Road

City

Huzhou

State

Country

CN

Zip

313200

Phone

86 57 2883 1088

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies